Search

Your search keyword '"Grünig, Ekkehard"' showing total 1,068 results

Search Constraints

Start Over You searched for: Author "Grünig, Ekkehard" Remove constraint Author: "Grünig, Ekkehard"
1,068 results on '"Grünig, Ekkehard"'

Search Results

151. Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry

152. Cardiac Rehabilitation in German Speaking Countries of Europe—Evidence-Based Guidelines from Germany, Austria and Switzerland LLKardReha-DACH—Part 1

154. Author Correction:Therapeutic potential of KLF2-induced exosomal microRNAs in pulmonary hypertension (Nature Communications, (2020), 11, 1, (1185), 10.1038/s41467-020-14966-x)

157. Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry

158. Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry

159. Bayesian Inference Associates Rare KDR Variants With Specific Phenotypes in Pulmonary Arterial Hypertension

160. sj-pdf-1-pul-10.1177_2045894020973124 - Supplemental material for Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study

161. sj-pdf-1-pul-10.1177_2045894020942121 - Supplemental material for Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)

162. Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry

163. Cardiac Rehabilitation in German Speaking Countries of Europe—Evidence-Based Guidelines from Germany, Austria and Switzerland LLKardReha-DACH—Part 1

164. Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension:A Double-Blind Placebo-controlled Clinical Trial

165. Right Atrial Pressure During Exercise Predicts Survival in Patients With Pulmonary Hypertension

166. Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry

169. Effect of Supervised Training Therapy on Pulmonary Arterial Compliance and Stroke Volume in Severe Pulmonary Arterial Hypertension and Inoperable or Persistent Chronic Thromboembolic Pulmonary Hypertension

170. The Experience, Prerequisites, and the Barriers in Organizing a Specialized Rehabilitation Program for Patients with Pulmonary Hypertension

172. ERS statement on chronic thromboembolic pulmonary hypertension

173. Response to: ‘ Correspondence on ‘Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension’’ by Iudici et al

174. Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial

179. Assessment of the REPLACE study composite endpoint in riociguat‐treated patients in the PATENT study

180. SWITCHING TO RIOCIGUAT IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION NOT AT TREATMENT GOAL WITH PHOSPHODIESTERASE TYPE-5 INHIBITORS: SUBGROUP ANALYSIS RESULTS OF THE REPLACE STUDY

181. Late Breaking Abstract - Switching from PDE5i to riociguat in patients with PAH: The REPLACE study

182. Genetic findings in patients with different forms of pulmonary hypertension

184. Supervised exercise training in patients with chronic thromboembolic pulmonary hypertension (CTEPH) as early follow-up treatment after pulmonary endarterectomy (PEA) – a prospective cohort study

185. Impact of SARS‐CoV‐2 pandemic on pulmonary hypertension out‐patient clinics in Germany: a multi‐centre study

186. Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry

187. Myeloproliferative Diseases as Possible Risk Factor for Development of Chronic Thromboembolic Pulmonary Hypertension—A Genetic Study

189. Comparison of MRI and VQ-SPECT as a Screening Test for Patients With Suspected CTEPH: CHANGE-MRI Study Design and Rationale

190. Genetic Predisposition to High-Altitude Pulmonary Edema

191. Flow rate variance of a fully implantable pump for the delivery of intravenous treprostinil in pulmonary arterial hypertension

193. Supervised Exercise Training in Patients with Chronic Thromboembolic Pulmonary Hypertension as Early Follow-Up Treatment after Pulmonary Endarterectomy: A Prospective Cohort Study

195. Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension

198. An open‐label, dose‐escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension.

199. Age-changes in right ventricular function–pulmonary circulation coupling: from pediatric to adult stage in 1899 healthy subjects. The RIGHT Heart International NETwork (RIGHT-NET).

200. Prognostic impact of hypochromic erythrocytes in patients with pulmonary arterial hypertension.

Catalog

Books, media, physical & digital resources